Dr Verna McErlane, Director of Commercial Operations, International at Sistemic, is scheduled to give her own special insight into advanced analytical models to support the stem cell therapy industry at this year’s Stem Cell Meeting on the MESA conference.
Sistemic, the cell characterisation problem-solving service provider that uses miRNA, is a strong advocate for the potential of regenerative medicine. Dr Verna McErlane, Sistemic’s Director of Commercial Operations, recently took part in a round-table discussion with leading stem cell researchers.
On the 24th March 2020 we let everyone know that in order to comply with the UK and Scottish Governments' lock down restrictions, the company would temporarily close at the end of the working day 24th March 2020.
We have now put the necessary IT infrastructure to allow all staff to work from home, and also the social distancing measures to allow lab work to be safely carried out in compliance with the UK and Scottish Governments' social distancing measures.
Sistemic are delighted to announce a new article published on RegMedNet titled “In vitro assays for residual pluripotent stem cells in derived cell therapy products: what’s the current state of play?”.
We are taking this opportunity to let you know that as of 20.30 GMT 23rd March 2020 the UK and Scottish Governments issued further legally enforced social distancing measures, and as part of this, have instructed all non-essential businesses to close with immediate effect. They have stated that this situation will be reviewed following an initial 3 week period, in the first instance.
We would like to provide you with an update regarding our plans for dealing with the COVID-19 outbreak, as well as our commitment to working with you on your important projects. We are following UK Public Health Policy and all Government advice to ensure that we fully comply with guidance as it occurs.